105 related articles for article (PubMed ID: 12383533)
1. Aspirin-induced inhibition of ovarian tumor cell growth.
Drake JG; Becker JL
Obstet Gynecol; 2002 Oct; 100(4):677-82. PubMed ID: 12383533
[TBL] [Abstract][Full Text] [Related]
2. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Aguilar Z; Akita RW; Finn RS; Ramos BL; Pegram MD; Kabbinavar FF; Pietras RJ; Pisacane P; Sliwkowski MX; Slamon DJ
Oncogene; 1999 Oct; 18(44):6050-62. PubMed ID: 10557094
[TBL] [Abstract][Full Text] [Related]
3. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
4. Aspirin effects on endometrial cancer cell growth.
Arango HA; Icely S; Roberts WS; Cavanagh D; Becker JL
Obstet Gynecol; 2001 Mar; 97(3):423-7. PubMed ID: 11239649
[TBL] [Abstract][Full Text] [Related]
5. [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].
Wang HJ; Peng ZL; Liu XQ; Yang KX; Lou JY; Luo FM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):428-32. PubMed ID: 17593823
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
7. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
8. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.
RodrÃguez-Burford C; Barnes MN; Oelschlager DK; Myers RB; Talley LI; Partridge EE; Grizzle WE
Clin Cancer Res; 2002 Jan; 8(1):202-9. PubMed ID: 11801560
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
Bijman MN; van Berkel MP; Kok M; Janmaat ML; Boven E
Anticancer Drugs; 2009 Jul; 20(6):450-60. PubMed ID: 19369859
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
Karlan BY; Jones J; Slamon DJ; Lagasse LD
Gynecol Oncol; 1994 Apr; 53(1):70-7. PubMed ID: 7909787
[TBL] [Abstract][Full Text] [Related]
11. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Mann M; Sheng H; Shao J; Williams CS; Pisacane PI; Sliwkowski MX; DuBois RN
Gastroenterology; 2001 Jun; 120(7):1713-9. PubMed ID: 11375952
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
13. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
14. ErbB receptor expression and growth response to heregulin beta 1 in five ovarian carcinoma lines.
Pegues JC; Kannan B; Stromberg K
Int J Oncol; 1999 Jun; 14(6):1169-76. PubMed ID: 10339675
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.
Hsu C; Huang CL; Hsu HC; Lee PH; Wang SJ; Cheng AL
Cancer; 2002 Jan; 94(2):415-20. PubMed ID: 11900227
[TBL] [Abstract][Full Text] [Related]
16. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
Jones J; Lagasse LD; Karlan BY
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
[TBL] [Abstract][Full Text] [Related]
17. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
Le XF; McWatters A; Wiener J; Wu JY; Mills GB; Bast RC
Clin Cancer Res; 2000 Jan; 6(1):260-70. PubMed ID: 10656457
[TBL] [Abstract][Full Text] [Related]
18. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
Hsieh CY; Chen CA; Chou CH; Lai KP; Jeng YM; Kuo ML; Wei LH
J Biomed Sci; 2004; 11(2):249-59. PubMed ID: 14966375
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
